Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone

AIM: The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. METHODS: In this randomized, double-blind, phase 3 study, patients (N = 342) received ca...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Forst, T, Guthrie, R, Goldenberg, R, Yee, J, Vijapurkar, U, Meininger, G, Stein, P
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2014
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237547/
https://ncbi.nlm.nih.gov/pubmed/24528605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12273
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky